| Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility International Multiple Sclerosis Genetics Consortium*†, ANZgene, ... Science 365 (6460), eaav7188, 2019 | 851 | 2019 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 461 | 2019 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 392 | 2016 |
| Geographical variations in sex ratio trends over time in multiple sclerosis M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ... PloS one 7 (10), e48078, 2012 | 260 | 2012 |
| Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ... Annals of neurology 80 (1), 89-100, 2016 | 206 | 2016 |
| Defining reliable disability outcomes in multiple sclerosis T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ... Brain 138 (11), 3287-3298, 2015 | 201 | 2015 |
| Sex as a determinant of relapse incidence and progressive course of multiple sclerosis T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ... Brain 136 (12), 3609-3617, 2013 | 195 | 2013 |
| Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ... Annals of Neurology 77 (3), 425-435, 2015 | 186 | 2015 |
| Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ... The Lancet Neurology 16 (4), 271-281, 2017 | 171 | 2017 |
| Fingolimod after natalizumab and the risk of short-term relapse VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ... Neurology 82 (14), 1204-1211, 2014 | 155 | 2014 |
| Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination MD Binder, HS Cate, AL Prieto, D Kemper, H Butzkueven, MM Gresle, ... Journal of Neuroscience 28 (20), 5195-5206, 2008 | 143 | 2008 |
| Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ... JAMA neurology 72 (4), 405-413, 2015 | 128 | 2015 |
| Towards personalized therapy for multiple sclerosis: prediction of individual treatment response T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ... Brain 140 (9), 2426-2443, 2017 | 114 | 2017 |
| Risk of relapse phenotype recurrence in multiple sclerosis T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, ... Multiple Sclerosis Journal 20 (11), 1511-1522, 2014 | 103 | 2014 |
| The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude J Lechner-Scott, B Spencer, T De Malmanche, J Attia, M Fitzgerald, ... Multiple Sclerosis Journal 18 (7), 974-982, 2012 | 95 | 2012 |
| Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis T Kalincik, EK Havrdova, D Horakova, G Izquierdo, A Prat, M Girard, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (4), 458-468, 2019 | 90 | 2019 |
| Epigenome-wide association studies: current knowledge, strategies and recommendations MP Campagna, A Xavier, J Lechner-Scott, V Maltby, RJ Scott, ... Clinical epigenetics 13, 1-24, 2021 | 84 | 2021 |
| Risk of secondary progressive multiple sclerosis: a longitudinal study A Fambiatos, V Jokubaitis, D Horakova, E Kubala Havrdova, M Trojano, ... Multiple Sclerosis Journal 26 (1), 79-90, 2020 | 81 | 2020 |
| Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years T Kalincik, I Diouf, S Sharmin, C Malpas, T Spelman, D Horakova, ... Neurology 96 (5), e783-e797, 2021 | 73 | 2021 |
| Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis N Lizak, A Lugaresi, R Alroughani, J Lechner-Scott, M Slee, E Havrdova, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (3), 196-203, 2017 | 72 | 2017 |
